1.Operative Treatment for Dorsal Lip Fracture of the Base of the Middle Phalanx.
Ho Jung KANG ; Hong Kyo MOON ; Sung Yong SUNG ; Soo Bong HAH
The Journal of the Korean Orthopaedic Association 2004;39(3):271-277
PURPOSE: To evaluate the clinical and radiological results of operative treatment for dorsal lip fracture of the base of the middle phalanx. MATERIALS AND METHODS: From 1992 to 2003 we experienced 9 cases of dorsal lip fracture of the middle phalangeal base that were treated surgically. Spinal needle fixation was used in cases with comminution. iniscrew fixation was performed in cases with a fragment larger than half of the articular surface. The pull-out technique was performed only in the cases with a fragment without comminution smaller than half of the articular surface. Bone union was evaluated using roentgenograms and clinical evaluations were done using Steel's scoring method. RESULTS: The average follow up after operation was 12.3 months. Cases showed union at an average of 7 weeks postoperatively. Two cases achieved excellent results, six cases good, and one case achieved a fair result; mean proximal interphalangeal joint flexion was 100 degrees (range 90-106). Extension deficit of 5 degrees was noted in 2 fingers. CONCLUSION: The pull-out technique, miniscrew fixation, and spinal needle fixation can produce a good clinical and radiological outcome in the treatment of dorsal lip fracture of the base of the middle phalanx.
Fingers
;
Follow-Up Studies
;
Joints
;
Lip*
;
Needles
;
Research Design
2.Anti-Helicobacter pylori, Anti-apoptotic, and Cytoprotective Effects of Threonine Synthesized from Corynebacterium glutamicum in Gastric Epithelial Cells
Jeong Min AN ; Yang Soo KIM ; Young Gi HONG ; Bong Soo HAH ; Mi Seo SOHN ; Ki Baik HAHM
The Korean Journal of Helicobacter and Upper Gastrointestinal Research 2019;19(4):245-256
BACKGROUND/AIMS: Among irritants causing gastric ulcer, Helicobacter pylori (H. pylori) might be pivotal, after which eradication became essential way in either inhibiting ulcerogenesis or preventing ulcer recurrence. Since threonine is essential in either mucus synthesis or cytoprotection, we hypothesized that the dietary threonine from Corynebacterium glutamicum (C. glutamicum) can mitigate the cytotoxicity of H. pylori infection.MATERIALS AND METHODS: RGM-1 cells were challenged with 100 multiplicity of infection H. pylori for 6 hours, during which threonine alone or combination with Corynebacterium sp. was administered and compared for anti-Helicobacter, anti-inflammation, anti-oxidative, and cytoprotective actions.RESULTS: Threonine alone or combination of threonine and C. glutamicum yielded significant bacteriostatic outcomes. The increased expressions of interleukin (IL)-1β, IL-8, Cox-2, and iNOS mRNA after H. pylori infection were significantly decreased with either threonine alone or the combination of threonine and C. glutamicum. The elevated expressions of NF-kB, HIF-1a, and c-jun after H. pylori infection were all significantly decreased with the combination of threonine and broth from C. glutamicum (P < 0.05), leading to significant decreases in 2′,7′-dichlorofluorescein-diacetate (P < 0.01). Tracing further host antioxidative response, the attenuated expression of heme oxygenase-1, Nrf2, and dehydrogenase quinone-1 after H. pylori infection was significantly preserved with combination of threonine and C. glutamicum. H. pylori infection led to significant increases in apoptosis accompanied with Bcl-2 decreases and Bax increases, while the combination of threonine and C. glutamicum significantly attenuated apoptosis, in which attenuated EGF, TGF-β, and VEGF were significantly regulated, while β-catenin did not change.CONCLUSIONS: Threonine synthesized from C. glutamicum significantly alleviated the cytotoxicity of H. pylori in gastric epithelial cells.
Apoptosis
;
Corynebacterium glutamicum
;
Corynebacterium
;
Cytoprotection
;
Epidermal Growth Factor
;
Epithelial Cells
;
Helicobacter pylori
;
Heme Oxygenase-1
;
Interleukin-8
;
Interleukins
;
Irritants
;
Mucus
;
NF-kappa B
;
Oxidative Stress
;
Oxidoreductases
;
Recurrence
;
RNA, Messenger
;
Stomach Ulcer
;
Thiram
;
Threonine
;
Ulcer
;
Vascular Endothelial Growth Factor A
3.The Treatment of Metastatic and Castration-Resistant Prostate Cancer Patients in Korea
Yoon Soo HAH ; U Syn HA ; Jin Woo JUNG ; Bong Hee PARK ; Hyung Joon KIM ; Ki Hong KIM ; Jeong Kyun YEO
Korean Journal of Urological Oncology 2019;17(1):48-59
The treatment of advanced prostate cancer has rapidly evolved. Androgen deprivation therapy is recognized as the first-line therapy for metastatic disease; however, a substantial proportion of patients will eventually progress to develop castration-resistance. For the past several years, docetaxel-based chemotherapy has shown significant therapeutic benefit in castration-resistant prostate cancer. Over the last 5 years, several new agents such as the enzalutamide, abiraterone, cabazitaxel, and 223radium have been developed which have all been associated with improved quality of life, pain palliation, and an increase in survival. Unfortunately, there are no Korean treatment guideline for metastatic prostate cancer and/or castration-resistant prostate cancer which has been developed based on adequate review and assessment of evidences. Thus, a guideline adequate for domestic circumstances is eagerly needed. The Korean Association for Clinical Oncology, the Korean Prostate Society, the Korean Urological Oncology Society, and the Korean Society of Pathologists reviewed and endorsed the guidelines.
Drug Therapy
;
Humans
;
Korea
;
Medical Oncology
;
Prostate
;
Prostatic Neoplasms
;
Quality of Life
4.Expression of vascular endothelial growth factor receptors in tumor and stromal cells of tongue squamous cell carcinoma.
Bong Wook PARK ; June Ho BYUN ; Young Sool HAH ; Deok Ryong KIM ; In Kyo CHUNG ; Jong Ryoul KIM ; Uk Kyu KIM ; Bong Soo PARK ; Gyoo Cheon KIM
Journal of the Korean Association of Oral and Maxillofacial Surgeons 2007;33(1):11-19
This study was to evaluate the expression of vascular endothelial growth factor receptors (VEGFRs) in tumor and stromal cells of tougue squamous cell carcinoma (SCC). We also wanted to characterize the differences, from the angiogenic aspect, between cancer-associated stromal cells and non-malignant stromal cells. Paraffin-embedded tumor specimens from eleven patients with tongue SCCs were studied. Immunohistochemical staining for VEGFR-1,-2, and -3 was performed on the tumor cells, stromal fibroblasts and tumor-associated macrophages of the specimens. The expression of all 3 receptors was detected in the tumor cells themselves of the biopsy specimens. All 3 receptors were also expressed on stromal cells, except that VEGFR-2 was not expressed in stromal fibroblasts. In radical excision specimens, the staining intensity for VEGFR-1, -2 in the tumor cells and VEGFR-1,-3 in the tumor-associated macrophages was significantly lower than that in the biopsy specimens (P < 0.05). By using the general marker of fibroblast and macrophage, 5B5 and CD68, respectively, we performed double immunofluorescence staining for 5B5 and each VEGFR in the stromal fibroblasts and for CD68 and each VEGFR in the tumor-associated macrophages of the radical excision specimens. We used 4 cases of fibroma and 4 cases of chronic inflammation tissue as the controls. It was found that only each marker was expressed in the control group, however, 5B5/VEGFR-1 and 5B5/VEGFR-3 in the stromal fibroblasts, and CD68/VEGFR-1 and CD68/VEGFR-3 in the tumor-associated macrophages were double stained in the radical excision specimens. Although our study used small number of specimens, the results of our study showed that in tongue SCC, in association with the angiogenesis, the stromal cells showed the activated phenotype and this was different from the nonmalignant stromal cells.
Biopsy
;
Carcinoma, Squamous Cell*
;
Fibroblasts
;
Fibroma
;
Fluorescent Antibody Technique
;
Humans
;
Inflammation
;
Macrophages
;
Phenotype
;
Receptors, Vascular Endothelial Growth Factor*
;
Stromal Cells*
;
Tongue*
;
Vascular Endothelial Growth Factor A*
;
Vascular Endothelial Growth Factor Receptor-1
;
Vascular Endothelial Growth Factor Receptor-2